Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT02724228
PHASE2

A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)

Sponsor: BioMarin Pharmaceutical

View on ClinicalTrials.gov

Summary

This is a Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children with Achondroplasia. The primary objective is to evaluate the long-term safety and tolerability of daily SC injections of BMN 111 in children with ACH who have completed two years of treatment in the 111-202 study.

Official title: A Phase 2, Open-Label, Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of BMN 111 in Children With Achondroplasia

Key Details

Gender

All

Age Range

7 Years - Any

Study Type

INTERVENTIONAL

Enrollment

30

Start Date

2016-01-26

Completion Date

2028-02

Last Updated

2026-03-13

Healthy Volunteers

No

Conditions

Interventions

DRUG

BMN 111

BMN 111 will be administered subcutaneously daily.

Locations (9)

Children's Hospital & Research Center Oakland

Oakland, California, United States

Harbor - UCLA Medical Center

Torrance, California, United States

Ann and Robert H. Lurie Childrens Hospital of Chicago

Chicago, Illinois, United States

Johns Hopkins McKusick - Institute of Genetic Medicine

Baltimore, Maryland, United States

Vanderbilt University

Nashville, Tennessee, United States

Baylor College of Medicine

Houston, Texas, United States

Murdoch Children's Research Institute

Parkville, Victoria, Australia

Institut Necker

Paris, France

Guys & St. Thomas NHS Foundation Trust Evelina Hospital

London, United Kingdom